Press release

Be The Match BioTherapies® and TrakCel Partner to Standardize Cell and Gene Therapy Supply Chain Solutions

Sponsored by Businesswire

The Match BioTherapies®
, an organization offering
solutions for companies developing and commercializing cell and gene
therapies, and TrakCel,
a software developer for cell and gene therapy supply chain tracking and
orchestration systems, today announce a collaboration that will provide
integrated solutions for companies developing cell and gene therapies.

This strategic partnership will enable cell and gene therapy developers
to benefit from an integrated suite of industry-leading services and
technology platforms. This combination of services and platforms has
been designed to improve operations at every step of the cell and gene
therapy supply chain. These steps range from clinical delivery to
commercial-scale operations and coordination of these activities through
a single software platform.

“Be The Match BioTherapies and TrakCel share the goal of ensuring that
the next generation of cell and gene therapies can be developed
efficiently and delivered to patients safely and reliably,” said Chris
McClain, vice president, Sales and New Business Development, Be The
Match BioTherapies. “This collaboration will allow us to develop the
custom solutions best suited for each individual program and patient

Be The Match BioTherapies and TrakCel will identify the unique
challenges faced by cell and gene therapy developers and integrate
services and platforms that provide direct solutions. Be The Match
BioTherapies will contribute solutions for cell sourcing, cell therapy
supply chain, clinical study design and execution, cellular therapy
outcomes registry, and IT systems. TrakCel will provide
its chain of custody/chain of identity (COC/COI), scheduling and
logistics management software platform. The integration will increase
efficiencies and eliminate redundancies while supporting all aspects of
the supply chain in accordance with regulatory and protocol
requirements. Both companies are already working together to deliver the
integrated offering in support of a client’s CAR-T development program.

“Clinical and commercial advances in cell and gene therapies continue to
progress dramatically. However, the resultant increases in complexity
and stakeholders involved in the supply chain can leave it stretched and
fragmented, potentially exposing patients to unnecessary risks,” said
Ravi Nalliah, CEO, TrakCel. “As a result, TrakCel is continuing to sign
partnerships with relevant industry providers to ensure the ever-growing
supply chain can be effectively managed. This specific partnership with
Be The Match BioTherapies will enable us to provide a more standardized
and streamlined cell and gene therapy development process. That, in
turn, will accelerate the delivery of vital new therapies to patients.”

About Be The Match BioTherapies®
The Match BioTherapies
 is the only cell and gene therapy solutions
provider with customizable services to support the end-to-end cell
therapy supply chain. Backed by the industry-leading experience of the National
Marrow Donor Program®/Be The Match®
, and a
research partnership with the CIBMTR® (Center
for International Blood and Marrow Transplant Research®), the
organization designs solutions that advance cell and gene therapies in
any stage of development.

Be The Match BioTherapies is dedicated to providing high-quality
cellular starting material consented for research, clinical and
commercial use, developing and managing expansive cell collection
networks, and navigating cell therapy regulatory compliance. Using
proven infrastructure to successfully manage cell therapy supply chains,
including MatchSource®
Supply Chain Software
, dedicated cell therapy supply chain case
managers and logistics experts, the organization has a history of
compliance managing the chain of identity. The collaboration with CIBMTR
extends services to include long-term follow-up tracking for the first
two FDA-approved CAR-T therapies.

For more information, follow Be The Match BioTherapies on LinkedIn or
Twitter at 

About TrakCel
TrakCel is the market leading designer,
developer and deliverer of integrated technologies specifically created
in 2012 to manage the international autologous and allogeneic cell, gene
and immunotherapy supply chain. TrakCel’s software platform has been
developed in collaboration with, and increasingly adopted by leading
companies in the cell, gene and immunotherapy industries. TrakCel’s
solutions deliver real-time control over the entire therapeutic supply
chain, from sample collection through manufacturing to treatment
delivery. The TrakCel platform accelerates global scale-up and scale-out
of cell and gene therapy products, increasing efficiency and decreasing
complexity, while maintaining needle-to-needle compliance and
traceability. TrakCel is headquartered in Cardiff, Wales, UK, with US
offices in California and New Jersey.

For more information, follow TrakCel on LinkedIn
or Twitter at